ZA200509929B - Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders - Google Patents

Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders Download PDF

Info

Publication number
ZA200509929B
ZA200509929B ZA200509929A ZA200509929A ZA200509929B ZA 200509929 B ZA200509929 B ZA 200509929B ZA 200509929 A ZA200509929 A ZA 200509929A ZA 200509929 A ZA200509929 A ZA 200509929A ZA 200509929 B ZA200509929 B ZA 200509929B
Authority
ZA
South Africa
Prior art keywords
disease
disorder
inflammatory
group
autoimmune
Prior art date
Application number
ZA200509929A
Other languages
English (en)
Inventor
Harats Dror
George Jacob
Halperin Gideon
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of ZA200509929B publication Critical patent/ZA200509929B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/13—Saturated ethers containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
ZA200509929A 2003-05-27 2005-12-07 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders ZA200509929B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/445,347 US6838452B2 (en) 2000-11-24 2003-05-27 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ZA200509929B true ZA200509929B (en) 2006-12-27

Family

ID=33489370

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509929A ZA200509929B (en) 2003-05-27 2005-12-07 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Country Status (16)

Country Link
US (10) US6838452B2 (fr)
EP (1) EP1626728B1 (fr)
JP (2) JP5255209B2 (fr)
KR (2) KR101122160B1 (fr)
CN (2) CN102040621B (fr)
AU (1) AU2004243695B2 (fr)
CA (1) CA2527483A1 (fr)
DK (1) DK1626728T3 (fr)
ES (1) ES2429134T3 (fr)
IL (1) IL172165A (fr)
MX (1) MXPA05012784A (fr)
NZ (1) NZ544285A (fr)
PT (1) PT1626728E (fr)
RU (3) RU2362567C2 (fr)
WO (1) WO2004106486A2 (fr)
ZA (1) ZA200509929B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295450B1 (fr) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Interleukine 10 pegylee
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20050119301A1 (en) * 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
ATE463254T1 (de) 2004-04-15 2010-04-15 Athera Biotechnologies Ab Antikörper gegen phosphorylcholinkonjugate
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
AU2007200090B2 (en) * 2004-07-09 2011-09-22 Vascular Biogenics Ltd. Improved Process for the Preparation of Oxidized Phospholipids
PL1773352T3 (pl) * 2004-07-09 2014-04-30 Vascular Biogenics Ltd Ulepszony sposób wytwarzania utlenionych fosfolipidów
US7183215B2 (en) * 2004-07-21 2007-02-27 Hewlett-Packard Development Company, L.P. Etching with electrostatically attracted ions
WO2006109170A2 (fr) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Polytherapie destinee au traitement de maladies cardiovasculaires et de pathologies associees
JP2009518424A (ja) * 2005-12-09 2009-05-07 ドラッグテック コーポレイション 必須脂肪酸乳剤の静脈投与
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
WO2007137864A1 (fr) * 2006-06-01 2007-12-06 Eucro European Contract Research Gmbh & Co. Kg Utilisation d'inhibiteurs du pp2c pour traiter ou prévenir l'artériosclérose
WO2008030604A2 (fr) 2006-09-08 2008-03-13 Rhode Island Hospital Traitement, prévention et élimination d'une maladie cérébrale d'origine alcoolique
EP2066336B1 (fr) 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Utilisation d'il-10 pégilée pour traiter un cancer
US8569529B2 (en) * 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) * 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
EP2117527B1 (fr) * 2007-02-08 2020-06-17 Med-Life Discoveries LP Composés pour utilisation dans le traitement de la démence senile de type alzheimer
CN101951921A (zh) * 2007-09-17 2011-01-19 比奥尼里斯有限责任公司 用于治疗恶病质的方法和手段
EP2242480A4 (fr) * 2007-10-16 2010-12-15 Vascular Biogenics Ltd Analogues du facteur d'activation des plaquettes (paf) et ses utilisations
MX2010004885A (es) * 2007-10-30 2010-08-04 Athera Biotechnologies Ab Diagnostico y metodos terapeuticos y composiciones para enfermedades cardiovasculares.
RU2367430C1 (ru) * 2008-04-16 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ прогноза эффективности лечения ревматоидного артрита симвастатином
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
EP2127639A1 (fr) * 2008-05-26 2009-12-02 Universiteit Utrecht Holding B.V. Liposomes contenant des corticostéroïdes pour le traitement des maladies cardiovasculaires
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2735578C (fr) 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Methode de determination de facteurs de risque de la maladie d'alzheimer comprenant des variants du gene tomm40
EP2348864A4 (fr) * 2008-10-08 2013-07-31 Vascular Biogenics Ltd Composés de thiophospholipides oxydés et leurs utilisations
EP2826370A3 (fr) * 2008-11-06 2015-04-08 Vascular Biogenics Ltd. Composés lipidiques oxydés et leurs utilisations
TWI475989B (zh) * 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法
DE102009007853A1 (de) * 2009-02-06 2010-08-12 LMU Ludwig-Maximilians-Universität München Mit Alkylphosphocholinen behandelte Intraokularlinsen zur pharmakologischen Nachstarprophylaxe
US20100291160A1 (en) * 2009-05-13 2010-11-18 Carver David R Pharmaceutical system for trans-membrane delivery
JP2013516457A (ja) * 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Ｖｂ−２０１を用いた併用治療法
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
US9222948B2 (en) * 2011-06-01 2015-12-29 Wake Forest University Health Sciences Methods of measuring amount of cholesteryl ester in a blood sample
DE102011103948A1 (de) * 2011-06-06 2012-12-06 B. Braun Melsungen Ag Biopassivierende Beschichtung von Gefäßprothesen mit Nitrocarbonsäuren enthaltenden Phospholipiden
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
CN103906532B (zh) 2011-08-09 2018-01-26 阿瑟拉生物技术公司 结合磷酰胆碱（pc）和/或pc结合物的抗体
HUE045163T2 (hu) 2011-08-09 2019-12-30 Athera Biotechnologies Ab Új ellenanyagok foszforilkolin ellen
CA2847218C (fr) * 2011-09-01 2018-02-27 Vascular Biogenics Ltd. Formulations et formes pharmaceutiques de phospholipides oxydes
SG11201400287XA (en) 2011-09-01 2014-03-28 Vertellus Specialties Inc Methods for producing biocompatible materials
US9006305B2 (en) 2011-09-01 2015-04-14 Vertellus Specialties Inc. Biocompatible material
GB201119363D0 (en) 2011-11-10 2011-12-21 Vertellus Specialities Inc Polymerisable material
ES2758923T3 (es) * 2011-12-12 2020-05-07 Vascular Biogenics Ltd Tratamiento de esteatohepatitis no alcohólica
EP2814497A4 (fr) * 2012-02-16 2015-12-09 Vascular Biogenics Ltd Procédés de traitement du psoriasis et de l'inflammation vasculaire
US9352049B2 (en) 2013-03-14 2016-05-31 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (fr) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
KR101639128B1 (ko) * 2013-10-29 2016-07-13 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
WO2015064960A1 (fr) * 2013-10-29 2015-05-07 울산대학교 산학협력단 Composition pharmaceutique servant à la prévention ou au traitement de maladies hépatiques contenant comme constituant efficace un précurseur de plasmalogène, un plasmalogène ou un analogue de plasmalogène
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
WO2016041013A1 (fr) * 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycérolipides et leurs utilisations
WO2016060996A2 (fr) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Compositions d'interleukine-15 et leurs utilisations
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3223824B1 (fr) * 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Lipides oxydés et traitement ou prévention de la fibrose
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
RU2635665C1 (ru) * 2017-02-16 2017-11-15 Общество с ограниченной ответственностью "БИОН" Способ получения l-a-глицерофосфорилхолина фармакопейного качества
KR101983298B1 (ko) * 2018-06-11 2019-05-29 연세대학교 산학협력단 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물
CN108864187B (zh) * 2018-08-06 2020-12-25 兰博尔开封科技有限公司 一种合成氧乐果重要中间体氧硫磷酯的工艺
AU2020225354B2 (en) * 2019-02-21 2025-03-06 Centre National De La Recherche Scientifique Structured molecular vectors for anti-inflammatory compounds and uses thereof
NL2025022B1 (en) * 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
JP6859562B1 (ja) * 2020-03-31 2021-04-14 株式会社 レオロジー機能食品研究所 脂肪肝改善用組成物
WO2022170134A2 (fr) * 2021-02-05 2022-08-11 Retrotope, Inc. Protocoles de dosage pour l'administration d'acide arachidonique deutéré ou d'un promédicament de celui-ci
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
CN118284615A (zh) * 2021-11-22 2024-07-02 株式会社食物流变功能研究所 化合物、其外消旋体、它们的盐、组合物、抗炎剂、痴呆症治疗剂及雷特综合征治疗剂
WO2024086663A1 (fr) * 2022-10-19 2024-04-25 Corner Therapeutics, Inc. Lipides d'ether pour l'hyperactivation de cellules dendritiques de mammifères
AU2024206259A1 (en) * 2023-01-03 2025-07-17 Baker Heart and Diabetes Institute Ether of phosphatidylcholine and phosphatidylethanolamine, their lyso-forms and mixture thereof for use in the treatment of a disease or disorder caused by a deficiency in plasmalogens
WO2026008716A1 (fr) * 2024-07-02 2026-01-08 Baker Heart and Diabetes Institute Méthodes d'utilisation de précurseurs de plasmalogène dans le traitement de maladies associées au plasmalogène

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) * 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4410237A (en) * 1980-09-26 1983-10-18 Massachusetts Institute Of Technology Method and apparatus for shaping electromagnetic beams
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
AT383130B (de) * 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
JPS6168494A (ja) * 1984-09-11 1986-04-08 Kao Corp 燐脂質誘導体およびそれを含有する消炎鎮痛剤
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
JPH0617307B2 (ja) * 1984-11-09 1994-03-09 武田薬品工業株式会社 抗腫瘍剤
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
US4711512A (en) * 1985-07-12 1987-12-08 Environmental Research Institute Of Michigan Compact head-up display
EP0225129B1 (fr) 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Dérivés phospholipidiques, leur préparation et leur utilisation
WO1987005904A1 (fr) * 1986-03-24 1987-10-08 The University Of Sydney Analogues antigeniques du facteur d'activation des thrombocytes (paf)
JPH01502022A (ja) * 1986-04-07 1989-07-13 ジ・アップジョン・カンパニー 駆虫薬第４級アルキルアシルヒドラゾン、使用方法および組成物
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JPS6354386A (ja) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPS63135395A (ja) * 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
JPH01258691A (ja) * 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JP2534894B2 (ja) 1988-06-24 1996-09-18 日本ケミファ株式会社 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤
JPH0248585A (ja) * 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US5237451A (en) * 1989-11-17 1993-08-17 Minnesota Mining And Manufacturing Company Beam shaping system using diffraction
US5082629A (en) * 1989-12-29 1992-01-21 The Board Of The University Of Washington Thin-film spectroscopic sensor
JPH03258740A (ja) 1990-03-06 1991-11-19 Kao Corp 液体油、その製造法及びこれを含有する化粧料
ES2019552A6 (es) * 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
JP2869572B2 (ja) 1990-05-14 1999-03-10 和光純薬工業株式会社 ホスファチジルコリン誘導体の製造方法
JPH0497201A (ja) 1990-08-10 1992-03-30 Matsushita Electric Ind Co Ltd ビームエキスパンド装置および回折格子の製造方法
CA2108144A1 (fr) 1991-03-06 1992-09-07 Jack A. Roth Methodes et compositions pour l'inhibition selective de l'expression genique
US5224198A (en) * 1991-09-30 1993-06-29 Motorola, Inc. Waveguide virtual image display
US5561052A (en) * 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
JPH06230225A (ja) 1993-02-03 1994-08-19 Nissan Motor Co Ltd 表示装置
JPH06250022A (ja) 1993-02-26 1994-09-09 Nissan Motor Co Ltd 表示装置
JP3623250B2 (ja) * 1993-06-23 2005-02-23 オリンパス株式会社 映像表示装置
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
EP0724743A1 (fr) 1993-10-22 1996-08-07 Kopin Corporation Systeme de visualisation monte au niveau de la tete
DE4440819A1 (de) * 1993-11-19 1995-05-24 Ciba Geigy Ag Photoempfindliche Zusammensetzungen
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
JPH07224076A (ja) * 1994-02-10 1995-08-22 Sagami Chem Res Center ホスホリパーゼａ２の阻害剤
AU1751795A (en) 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP3364313B2 (ja) 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
US6579697B1 (en) 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
JPH07326065A (ja) * 1994-05-27 1995-12-12 Hitachi Ltd 光情報処理装置
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
JP4259611B2 (ja) * 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5506929A (en) * 1994-10-19 1996-04-09 Clio Technologies, Inc. Light expanding system for producing a linear or planar light beam from a point-like light source
JPH08208548A (ja) 1995-02-01 1996-08-13 Kao Corp グリセリン誘導体の製造法
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US5916763A (en) 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
US6825980B2 (en) * 1995-12-18 2004-11-30 Metrologic Instruments, Inc. DOE-based systems and devices for producing laser beams having modified beam characteristics
AU719629B2 (en) 1996-11-08 2000-05-11 Oklahoma Medical Research Foundation Endothelium specific expression regulated by EPCR control elements
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6206917B1 (en) 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US6204055B1 (en) 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
EP0909532A1 (fr) 1997-10-16 1999-04-21 Development Center For Biotechnology Matériau poreux et compatible avec l'environnement contenant des nématodes benefiques et sa préparation
JP2001521786A (ja) 1997-10-30 2001-11-13 ザ ジュネラル ホスピタル コーポレーション 単離軟骨細胞を使用した軟骨性基質の接着
ATE254291T1 (de) * 1998-04-02 2003-11-15 Elop Electrooptics Ind Ltd Optische holographische vorrichtungen
CA2331844A1 (fr) 1998-05-07 1999-11-11 University Of Maryland, Baltimore Methode de diagnostic et de traitement du syndrome de douleur pelvienne chronique
US6239151B1 (en) 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
DE19838837A1 (de) 1998-08-27 2000-03-02 Boehringer Ingelheim Int Zellspezifische Promoter des Entkopplungsproteins 3
US20020164434A1 (en) 1998-09-29 2002-11-07 Michael Tarvin Ultra violet light curable floor coating with coloring agent
JP2002532553A (ja) * 1998-12-21 2002-10-02 インケイサ．ソシエダ アノニマ 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用
US6414168B1 (en) * 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
JP3622556B2 (ja) 1999-02-23 2005-02-23 セイコーエプソン株式会社 照明光学系および投写型表示装置
IL130608A0 (en) 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
AU1226001A (en) * 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
JP4829454B2 (ja) * 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6687360B2 (en) * 1999-12-30 2004-02-03 At&T Corp. Personal IP follow-me service
TWI238183B (en) * 2000-01-12 2005-08-21 Sumitomo Chemical Co Polymeric fluorescent substance and polymer light-emitting device
US6265216B1 (en) 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
AU2001249762B2 (en) * 2000-03-31 2006-03-30 The Regents Of The University Of California A functional assay of high-density lipoprotein
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
JP2002122783A (ja) * 2000-10-13 2002-04-26 Olympus Optical Co Ltd 観察光学系及び撮像光学系及びそれを用いた装置
AU2002210574B2 (en) 2000-10-25 2006-08-24 Allnex Netherlands B.V. Photoactivatable water borne coating composition
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
ES2425321T3 (es) 2000-11-17 2013-10-14 Vascular Biogenics Ltd. Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2002041827A2 (fr) * 2000-11-24 2002-05-30 Vascular Biogenics Ltd. Procedes faisant appels a des phospholipides oxydes definis, ainsi que compositions contenant ces derniers, pour la prevention et le traitement de l'atherosclerose
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002230058B2 (en) 2001-01-29 2005-11-17 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US6458588B1 (en) * 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
KR20020083737A (ko) * 2001-04-30 2002-11-04 삼성전자 주식회사 착용형 디스플레이 시스템
US6438802B1 (en) 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003013434A2 (fr) * 2001-08-06 2003-02-20 Genomed, Llc Methodes et compositions destinees au traitement de maladies associees a des taux excessifs d'ace
US6833955B2 (en) * 2001-10-09 2004-12-21 Planop Planar Optics Ltd. Compact two-plane optical device
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
DE10155095A1 (de) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh Alkyl(en)ylglycerinethercarbonsäuren
KR100450815B1 (ko) 2002-02-01 2004-10-01 삼성전자주식회사 조명계 및 이를 채용한 프로젝션 디스플레이 장치
US6757105B2 (en) 2002-04-25 2004-06-29 Planop Planar Optics Ltd. Optical device having a wide field-of-view for multicolor images
US7023622B2 (en) * 2002-08-06 2006-04-04 Dmetrix, Inc. Miniature microscope objective lens
US6805490B2 (en) * 2002-09-30 2004-10-19 Nokia Corporation Method and system for beam expansion in a display device
EP1577872A4 (fr) 2002-12-26 2008-11-26 Sanyo Electric Co Dispositif de presentation video du type a projection
JP2005050666A (ja) 2003-07-28 2005-02-24 Tokai Rubber Ind Ltd 燃料電池用ホース材料およびそれを用いてなる燃料電池用ホース
AU2004269409A1 (en) 2003-08-29 2005-03-10 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
US7184617B2 (en) * 2004-03-12 2007-02-27 Matsushita Electric Industrial Co., Ltd. Portable device
US7177398B2 (en) * 2004-03-13 2007-02-13 Intrado Inc. Bi-directional messaging for an emergency services network
US7123693B2 (en) * 2004-03-13 2006-10-17 Intrado Inc. Method and apparatus for increasing the reliability of an emergency call communication network
PL1773352T3 (pl) 2004-07-09 2014-04-30 Vascular Biogenics Ltd Ulepszony sposób wytwarzania utlenionych fosfolipidów
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
EP1786904A4 (fr) 2004-08-09 2010-06-16 Merck Sharp & Dohme Compositions de vecteurs adenoviraux
KR101157230B1 (ko) * 2004-08-17 2012-06-15 삼성코닝정밀소재 주식회사 나노 기공을 포함하는 물질을 형성하기 위한 조성물
US20060056028A1 (en) * 2004-09-13 2006-03-16 Wildnauer Kenneth R Apodized diffraction grating with improved dynamic range
US20060194765A1 (en) * 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US7206107B2 (en) * 2004-12-13 2007-04-17 Nokia Corporation Method and system for beam expansion in a display device
US20090232808A1 (en) 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US8252775B2 (en) * 2005-07-21 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Method of treating multiple sclerosis with phosphocholine containing lipids
WO2007027905A2 (fr) 2005-08-31 2007-03-08 Science And Technology Corporation @ Unm Cellules souches renales humaines
WO2007031991A2 (fr) 2005-09-14 2007-03-22 Mirage Innovations Ltd. Dispositif optique a diffraction et systeme
US20080043334A1 (en) 2006-08-18 2008-02-21 Mirage Innovations Ltd. Diffractive optical relay and method for manufacturing the same
EP1764095A1 (fr) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux derivés de nitrocatéchol ayant activité de ligande de selectine
US20090128902A1 (en) 2005-11-03 2009-05-21 Yehuda Niv Binocular Optical Relay Device
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2007138576A1 (fr) 2006-05-25 2007-12-06 Mirage Innovations Ltd. systÈme d'Éclairage avec intÉgrateur optique pour projecteur d'image
JP2008037763A (ja) 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
KR20090011223A (ko) 2007-07-25 2009-02-02 삼성전자주식회사 방송처리장치 및 그 제어방법
CA2702437C (fr) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Procede pour retarder le debut d'une sclerose en plaques cliniquement definie
EP2348864A4 (fr) 2008-10-08 2013-07-31 Vascular Biogenics Ltd Composés de thiophospholipides oxydés et leurs utilisations
EP2826370A3 (fr) 2008-11-06 2015-04-08 Vascular Biogenics Ltd. Composés lipidiques oxydés et leurs utilisations
US20110083464A1 (en) 2009-10-12 2011-04-14 Craig Kettles Refrigerator with a Pullout Refrigerator Compartment
JP2013516457A (ja) 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Ｖｂ−２０１を用いた併用治療法
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
CA2847218C (fr) 2011-09-01 2018-02-27 Vascular Biogenics Ltd. Formulations et formes pharmaceutiques de phospholipides oxydes

Also Published As

Publication number Publication date
US7893291B2 (en) 2011-02-22
US20110189212A1 (en) 2011-08-04
MXPA05012784A (es) 2006-02-28
US7973023B2 (en) 2011-07-05
EP1626728A2 (fr) 2006-02-22
US7902176B2 (en) 2011-03-08
RU2005140666A (ru) 2006-06-27
EP1626728B1 (fr) 2013-07-10
JP2013079247A (ja) 2013-05-02
CN102040621A (zh) 2011-05-04
US7186704B2 (en) 2007-03-06
US20050272813A1 (en) 2005-12-08
US7625882B2 (en) 2009-12-01
US20070099868A1 (en) 2007-05-03
DK1626728T3 (da) 2013-09-30
AU2004243695A1 (en) 2004-12-09
CA2527483A1 (fr) 2004-12-09
US20080261865A1 (en) 2008-10-23
HK1088234A1 (en) 2006-11-03
PT1626728E (pt) 2013-10-08
EP1626728A4 (fr) 2009-09-02
IL172165A (en) 2015-10-29
CN1826122A (zh) 2006-08-30
RU2013107800A (ru) 2014-08-27
US20120329757A1 (en) 2012-12-27
WO2004106486A2 (fr) 2004-12-09
ES2429134T3 (es) 2013-11-13
JP5255209B2 (ja) 2013-08-07
KR101081977B1 (ko) 2011-11-09
KR20110036125A (ko) 2011-04-06
US20090209775A1 (en) 2009-08-20
RU2362567C2 (ru) 2009-07-27
WO2004106486A3 (fr) 2005-01-06
US8563534B2 (en) 2013-10-22
US8501715B2 (en) 2013-08-06
US20030225035A1 (en) 2003-12-04
RU2009112686A (ru) 2010-10-20
US7504388B2 (en) 2009-03-17
US20110097350A1 (en) 2011-04-28
US8158611B2 (en) 2012-04-17
JP2007531706A (ja) 2007-11-08
AU2004243695B2 (en) 2010-12-02
US20100048515A1 (en) 2010-02-25
KR20060006973A (ko) 2006-01-20
NZ544285A (en) 2008-11-28
US20040106677A1 (en) 2004-06-03
KR101122160B1 (ko) 2012-04-12
US6838452B2 (en) 2005-01-04
CN1826122B (zh) 2010-12-22
CN102040621B (zh) 2016-01-20
RU2482854C2 (ru) 2013-05-27

Similar Documents

Publication Publication Date Title
EP1626728B1 (fr) Lipides oxydes et leur utilisation dans le traitement de maladies et de troubles inflammatoires
CA2429817C (fr) Procedes faisant appels a des phospholipides oxydes definis, ainsi que compositions contenant ces derniers, pour la prevention et le traitement de l'atherosclerose
HK1088234B (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
IL176976A (en) Use of oxygenated phospholipids defined for the preparation of a medicinal product for the treatment of atherosclerosis and other vascular diseases
HK1164121A (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis